Tag Archives: Celgene
By Pharm Exec | Published: April 29, 2014
The pancreatic cancer market is set to climb from $855.8 million in 2012 to approximately $1.21 billion by 2019 (a CAGR of 5.1%), says a report from GBI Research. The growth will be fueled by increasing global prevalence of the disease, coupled with the launch at least three new drugs: the recently approved Abraxane (Celgene), […]
By Clark Herman | Published: September 27, 2013
Vaccines–once the neglected also ran in big Pharma’s armamentarium of innovations–received top billing at PhRMA’s annual Research and Hope awards held at the Washington Newseum on September 11. More than 200 industry executives, politicians and scientists recognized the accomplishments of three separate teams in developing and building access to preventive vaccines.
By admin | Published: September 25, 2008
Click here to view a slideshow from Prix Galien 2008 The 2008 Prix Galien USA is in the books, and Pharm Exec was in attendance at New York’s Museum of Natural History to take in all the festivities. Pfizer, Merck, Alexion, Wyeth, and Celgene were all recognized for their work in advancing science in both […]